“…Inhibition of fibrinolytic proteases is another relevant segment of the characterization; inhibitors can act on enzymes by modifying structural characteristics that determine their mechanism of action and consequently inhibit enzymatic activity (Vargas, 2020). According to the studies analyzed, several compounds were able to inhibit the activity of the enzymes studied, these were PMSF (serine protease inhibitor) (Kim et al, 2011;Choi et al, 2011;Liu et al, 2017;Moon et al, 2014;Liu et al, 2015;Liu et al, 2016;Nascimento et al, 2016;Nascimento et al, 2017;Shirasaka et al, 2012;Cleentino et al, 2011); EDTA (metalloprotease inhibitor) (Guggisberg et al, 2011;Xiao-Ian et al, 2014;Andrade et al, 2018;Lins et al, 2019); SBTI (serine protease inhibitor) (Liu et al, 2016;Liu et al, 2017;Deng et al, 2018;Li et al, 2020); Aprotinin (Inhibitor of serine and cysteine protease) (Liu et al, 2016); TPCK (serine protease inhibitor) (Shirasaka et al, 2021); EGTA (metalloprotease inhibitor) (Choi et al, 2013;Meschram et al, 2016;Andrade et al, 2018;Lins et al, 2019;Choi et al, 2016) and β-mercaptoethanol (cysteine protease inhibitor) (Clementino et al, 2019).…”